The Risk of Pneumothorax With Intrapleural Urokinase in Children With Parapneumonic Effusion.

IF 2.7 3区医学 Q1 PEDIATRICS Pediatric Pulmonology Pub Date : 2025-01-01 Epub Date: 2024-12-13 DOI:10.1002/ppul.27443

Gili Kadmon, Adi Schoen, Elhanan Nahum, Avichai Weissbach, Eytan Kaplan, Tal Cohen, Gabriel Chodick, Oded Scheuerman

{"title":"The Risk of Pneumothorax With Intrapleural Urokinase in Children With Parapneumonic Effusion.","authors":"Gili Kadmon, Adi Schoen, Elhanan Nahum, Avichai Weissbach, Eytan Kaplan, Tal Cohen, Gabriel Chodick, Oded Scheuerman","doi":"10.1002/ppul.27443","DOIUrl":null,"url":null,"abstract":"Aim: Fibrinolytic therapy is commonly used in children with parapneumonic effusion, to facilitate drainage of the effusions and recovery. However, data regarding complications of this treatment in children are limited. We aimed to determine the incidence of pneumothorax (PNX) associated with intrapleural urokinase.Methods: We analyzed retrospectively collected data of children with parapneumonic effusion who underwent chest drain insertion. The clinical course and complications, including the incidence of PNX, were compared between children who were and were not treated with urokinase.Results: The study group included 120 children, of whom 57 were treated with urokinase. Children who were and were not treated with urokinase did not differ in markers of disease severity or in the length of hospitalization. Among the patients treated with urokinase compared to those not treated, the incidence of PNX was higher (35% vs. 6%, p < 0.001) and the median duration of chest drain treatment was longer (6 vs. 4 days, p < 0.001).Conclusion: In our pediatric cohort, intrapleural urokinase was associated with a higher incidence of PNX and did not shorten the duration of hospitalization.","PeriodicalId":19932,"journal":{"name":"Pediatric Pulmonology","volume":" ","pages":"e27443"},"PeriodicalIF":2.7000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatric Pulmonology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/ppul.27443","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/13 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"PEDIATRICS","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: Fibrinolytic therapy is commonly used in children with parapneumonic effusion, to facilitate drainage of the effusions and recovery. However, data regarding complications of this treatment in children are limited. We aimed to determine the incidence of pneumothorax (PNX) associated with intrapleural urokinase.

Methods: We analyzed retrospectively collected data of children with parapneumonic effusion who underwent chest drain insertion. The clinical course and complications, including the incidence of PNX, were compared between children who were and were not treated with urokinase.

Results: The study group included 120 children, of whom 57 were treated with urokinase. Children who were and were not treated with urokinase did not differ in markers of disease severity or in the length of hospitalization. Among the patients treated with urokinase compared to those not treated, the incidence of PNX was higher (35% vs. 6%, p < 0.001) and the median duration of chest drain treatment was longer (6 vs. 4 days, p < 0.001).

Conclusion: In our pediatric cohort, intrapleural urokinase was associated with a higher incidence of PNX and did not shorten the duration of hospitalization.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

胸膜腔内尿激酶治疗副肺积液患儿的气胸风险

目的：纤维蛋白溶解疗法常用于患有副肺积液的儿童，以促进积液引流和康复。然而，有关这种疗法在儿童中的并发症的数据却很有限。我们旨在确定与胸腔内尿激酶相关的气胸（PNX）发生率：我们分析了回顾性收集的、接受胸腔引流管插入术的副肺积液患儿的数据。结果：研究组包括 120 名患儿，其中有 3 名患儿接受了胸腔引流管置入术，有 2 名患儿未接受尿激酶治疗：研究组包括 120 名儿童，其中 57 人接受了尿激酶治疗。接受和未接受尿激酶治疗的儿童在疾病严重程度和住院时间上没有差异。与未接受尿激酶治疗的患儿相比，接受尿激酶治疗的患儿PNX的发生率更高（35% 对 6%，P 结论：在我们的儿科队列中，尿激酶治疗的患儿PNX的发生率较高：在我们的儿科队列中，胸膜腔内尿激酶与较高的 PNX 发生率有关，但并未缩短住院时间。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Pediatric Pulmonology 医学-呼吸系统

CiteScore

6.00

自引率

12.90%

发文量

468

审稿时长

3-8 weeks

期刊介绍： Pediatric Pulmonology (PPUL) is the foremost global journal studying the respiratory system in disease and in health as it develops from intrauterine life though adolescence to adulthood. Combining explicit and informative analysis of clinical as well as basic scientific research, PPUL provides a look at the many facets of respiratory system disorders in infants and children, ranging from pathological anatomy, developmental issues, and pathophysiology to infectious disease, asthma, cystic fibrosis, and airborne toxins. Focused attention is given to the reporting of diagnostic and therapeutic methods for neonates, preschool children, and adolescents, the enduring effects of childhood respiratory diseases, and newly described infectious diseases. PPUL concentrates on subject matters of crucial interest to specialists preparing for the Pediatric Subspecialty Examinations in the United States and other countries. With its attentive coverage and extensive clinical data, this journal is a principle source for pediatricians in practice and in training and a must have for all pediatric pulmonologists.